Analysis of regional hemodynamic regulation in response to scald injury.
Ultrasonic probes were placed around dog femoral arteries to record blood flow. Hind paw scalding with boiling water (5 s) caused a marked increase in ipsilateral femoral blood flow that persisted for the 2-h observation period. Contralateral femoral blood flow and systemic and pulmonary vascular resistances were unchanged. Compared to scald only animals, methysergide pretreatment diminished and shortened the femoral vasodilator response to scald (109 +/- 14 vs 243 +/- 27 ml/min at 5 min; 59 +/- 14 vs 191 +/- 31 ml/min at 2 h). Pretreatment with ritanserin, BW A1433U83, atropine, ICI 118551, diphenhydramine, ranitidine, meclofenamate, L-nitro-arginine methyl ester, 3-amino-1,2,4-triazine, and U 37883A had no effect on the increased femoral blood flow response to scald, suggesting this vasodilator response is not dependent upon activation of serotonergic2, adenosineA1, muscarinic, beta 2-adrenergic, histaminergic1 or histaminergic2 receptors, on cyclooxygenase products, endothelium-derived relaxing factor derived from nitric oxide (NO) synthase III, NO derived from NO synthase II, or KATP channels, respectively. Methysergide given after burn immediately reduced the augmented femoral blood flow to preburn levels, suggesting the vasodilator response to scald is mediated through continual activation of local serotonergic1-like receptors, which may be target site(s) for therapeutic interventions to influence burn-induced hemodynamic alterations.
Taheri
P A
PA
Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana 70112.
Lippton
H L
HL
Force
S D
SD
Franklin
E W
EW
Hyman
A L
AL
Flint
L M
LM
Ferrara
J J
JJ
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002056:Burns / Q000503:physiopathology*; D004155:Diphenhydramine / Q000494:pharmacology; D004285:Dogs; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D006614:Hindlimb / Q000098:blood supply; D006632:Histamine / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008469:Meclofenamic Acid / Q000494:pharmacology; D008729:Methoxamine / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology*; D009025:Morpholines / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000000981:diagnostic imaging / Q000503:physiopathology*; D019331:NG-Nitroarginine Methyl Ester; D005996:Nitroglycerin / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects; D011899:Ranitidine / Q000494:pharmacology; D012039:Regional Blood Flow; D016713:Ritanserin / Q000494:pharmacology*; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013997:Time Factors; D014227:Triazines / Q000494:pharmacology; D014463:Ultrasonography; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014700:Verapamil / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D009025:Morpholines; D017366:Serotonin Receptor Agonists; D014227:Triazines; D014970:Xanthines; C085327:3-amino-1,2,4-triazine; D016713:Ritanserin; D012701:Serotonin; D008469:Meclofenamic Acid; C082658:U 37883A; D001285:Atropine; D006632:Histamine; D011899:Ranitidine; D004155:Diphenhydramine; C047087:5-carboxamidotryptamine; C053414:BW A1433U; D001120:Arginine; D014700:Verapamil; D005996:Nitroglycerin; D008729:Methoxamine; D007545:Isoproterenol; D000218:Adamantane; D019331:NG-Nitroarginine Methyl Ester; D008784:Methysergide